Skip to main content
Erschienen in: HNO 7/2016

10.06.2016 | Leitthema

Oncologic treatment landscape for head and neck squamous cell carcinoma

Treatment infrastructure in German-speaking countries

verfasst von: J. Kimmeyer, T. Kurzweg, T. K. Hoffmann, R. Knecht, J. A. Veit, N. Möckelmann, A. Münscher, Dr. S. Laban

Erschienen in: HNO | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

The treatment of head and neck squamous cell carcinoma (HNSCC) is highly complex and requires a multimodal approach. However, guidelines for the treatment of most forms of HNSCC do not exist in German-speaking countries with the exception of oral cavity cancer. The aim of this cross-sectional study was to describe the current treatment landscape and infrastructure in German-speaking countries.

Methods

From November 2013 to July 2014, 204 departments of otorhinolaryngology (ORL) in Germany, Austria, and the German-speaking part of Switzerland were contacted and invited to take part in a web-based survey on the treatment of HNSCC. In order to cover the study in its entirety, we published three consecutive papers of which this paper is the first.

Results

In all, 62 treatment centers (30.4 %) participated in the survey. These centers included 21 university hospitals, 16 certified cancer centers, and 35 large centers, which diagnose at least 75 HNSCC patients annually. In 91.9 % of all cases, there were outpatient consultation hours (that were monodisciplinary in 61.4 %). A multidisciplinary tumor board was existent in 98.4 % of the cases. Of 62 ORL departments, 50 had a hospital cancer registry, 41 of 62 conducted oncological studies, and 35 of 62 assessed their patients’ quality of life.

Conclusion

The infrastructure of the treatment for HNSCC can be considered mostly well-developed and supports interdisciplinary cooperation. Potential improvements can be made regarding the standardization of tumor boards, the participation in clinical trials, and the availability of cancer registries and the data gathered therein.
Literatur
1.
Zurück zum Zitat Adelstein DJ, Li Y, Adams GL et al (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92–98CrossRefPubMed Adelstein DJ, Li Y, Adams GL et al (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92–98CrossRefPubMed
2.
Zurück zum Zitat Curran D, Giralt J, Harari PM et al (2007) Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with Cetuximab. J Clin Oncol 25:2191–2197CrossRefPubMed Curran D, Giralt J, Harari PM et al (2007) Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with Cetuximab. J Clin Oncol 25:2191–2197CrossRefPubMed
3.
Zurück zum Zitat De Bree R, Putten LVD, Brouwer J et al (2009) Detection of locoregional recurrent head and neck cancer after (chemo)radiotherapy using modern imaging. Oral Oncology 45:386–393 De Bree R, Putten LVD, Brouwer J et al (2009) Detection of locoregional recurrent head and neck cancer after (chemo)radiotherapy using modern imaging. Oral Oncology 45:386–393
4.
Zurück zum Zitat De Casso C, Visvanathan V, Soni-Jaiswall A et al (2012) Predictive value of positron emission tomography – computed tomography image fusion in the diagnosis of head and neck cancer: does it really improve staging and management? J Laryngol Otol 126:295–301CrossRefPubMed De Casso C, Visvanathan V, Soni-Jaiswall A et al (2012) Predictive value of positron emission tomography – computed tomography image fusion in the diagnosis of head and neck cancer: does it really improve staging and management? J Laryngol Otol 126:295–301CrossRefPubMed
5.
Zurück zum Zitat Evangelista L, Cervino AR, Chondrogiannis S et al (2014) Comparison between anatomical cross-sectional imaging and 18F-FDG PET/CT in the staging, restaging, treatment response, and long-term surveillance of squamous cell head and neck cancer: a systematic literature overview. Nucl Med Commun 35:123–134 (110.1097/MNM.0000000000000022)CrossRefPubMed Evangelista L, Cervino AR, Chondrogiannis S et al (2014) Comparison between anatomical cross-sectional imaging and 18F-FDG PET/CT in the staging, restaging, treatment response, and long-term surveillance of squamous cell head and neck cancer: a systematic literature overview. Nucl Med Commun 35:123–134 (110.1097/MNM.0000000000000022)CrossRefPubMed
6.
Zurück zum Zitat Guntinas-Lichius O, Rühlow S, Veelken F et al (2009) Quality of life during first-line palliative chemotherapy for recurrent and metastatic head and neck cancer with weekly cisplatin and docetaxel. J Cancer Res Clin Oncol 135:901–908CrossRefPubMed Guntinas-Lichius O, Rühlow S, Veelken F et al (2009) Quality of life during first-line palliative chemotherapy for recurrent and metastatic head and neck cancer with weekly cisplatin and docetaxel. J Cancer Res Clin Oncol 135:901–908CrossRefPubMed
7.
Zurück zum Zitat Guntinas-Lichius O, Wendt T, Buentzel J et al (2010) Head and neck cancer in Germany: a site-specific analysis of survival of the Thuringian cancer registration database. J Cancer Res Clin Oncol 136:55–63CrossRefPubMed Guntinas-Lichius O, Wendt T, Buentzel J et al (2010) Head and neck cancer in Germany: a site-specific analysis of survival of the Thuringian cancer registration database. J Cancer Res Clin Oncol 136:55–63CrossRefPubMed
8.
Zurück zum Zitat Haddad R, O’Neill A, Rabinowits G et al (2013) Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 14:257–264CrossRefPubMed Haddad R, O’Neill A, Rabinowits G et al (2013) Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 14:257–264CrossRefPubMed
9.
Zurück zum Zitat Kaatsch P, Spix C, Hentschel S et al (2013) Beiträge zur Gesundheitsberichterstattung des Bundes – Krebs in Deutschland 2009/2010. Robert-Koch-Institut, Berlin Kaatsch P, Spix C, Hentschel S et al (2013) Beiträge zur Gesundheitsberichterstattung des Bundes – Krebs in Deutschland 2009/2010. Robert-Koch-Institut, Berlin
10.
Zurück zum Zitat Kuhn FP, Hüllner M, Mader CE et al (2014) Contrast-enhanced PET/MR imaging versus contrast-enhanced PET/CT in head and neck cancer: How much MR information is needed? J Nucl Med 55:551–558CrossRefPubMed Kuhn FP, Hüllner M, Mader CE et al (2014) Contrast-enhanced PET/MR imaging versus contrast-enhanced PET/CT in head and neck cancer: How much MR information is needed? J Nucl Med 55:551–558CrossRefPubMed
11.
Zurück zum Zitat Mesía R, Rivera F, Kawecki A et al (2010) Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 21:1967–1973CrossRefPubMedPubMedCentral Mesía R, Rivera F, Kawecki A et al (2010) Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 21:1967–1973CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Murphy BA, Gilbert J, Cmelak A et al (2007) Symptom control issues and supportive care of patients with head and neck cancers. Clin Adv Hematol Oncol 5:807–822PubMed Murphy BA, Gilbert J, Cmelak A et al (2007) Symptom control issues and supportive care of patients with head and neck cancers. Clin Adv Hematol Oncol 5:807–822PubMed
13.
Zurück zum Zitat Nguyen NP, Vos P, Lee H et al (2008) Impact of tumor board recommendations on treatment outcome for locally advanced head and neck cancer. Oncology 75:186–191CrossRefPubMed Nguyen NP, Vos P, Lee H et al (2008) Impact of tumor board recommendations on treatment outcome for locally advanced head and neck cancer. Oncology 75:186–191CrossRefPubMed
14.
Zurück zum Zitat Pignon J‑P, Maître AL, Maillard E et al (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4–14CrossRefPubMed Pignon J‑P, Maître AL, Maillard E et al (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4–14CrossRefPubMed
15.
Zurück zum Zitat Pignon JP, Bourhis J, Domenge C et al (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 355:949–955CrossRefPubMed Pignon JP, Bourhis J, Domenge C et al (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 355:949–955CrossRefPubMed
16.
Zurück zum Zitat Psyrri A, Licitra L, Lacombe D et al (2010) Strategies to promote translational research within the European Organisation for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group: a report from the Translational Research Subcommittee. Ann Oncol 21:1952–1960CrossRefPubMedPubMedCentral Psyrri A, Licitra L, Lacombe D et al (2010) Strategies to promote translational research within the European Organisation for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group: a report from the Translational Research Subcommittee. Ann Oncol 21:1952–1960CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Singer S, Arraras JI, Baumann I et al (2013) Quality of life in patients with head and neck cancer receiving targeted or multimodal therapy – Update of the EORTC QLQ-H&N35, Phase I. Head Neck 35:1331–1338CrossRefPubMed Singer S, Arraras JI, Baumann I et al (2013) Quality of life in patients with head and neck cancer receiving targeted or multimodal therapy – Update of the EORTC QLQ-H&N35, Phase I. Head Neck 35:1331–1338CrossRefPubMed
18.
Zurück zum Zitat Van Herpen CML, Mauer ME, Mesia R et al (2010) Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5‑fluorouracil and cisplatin (TPF), 5‑fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323). Br J Cancer 103:1173–1181CrossRefPubMedPubMedCentral Van Herpen CML, Mauer ME, Mesia R et al (2010) Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5‑fluorouracil and cisplatin (TPF), 5‑fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323). Br J Cancer 103:1173–1181CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Wheless SA, Mckinney KA, Zanation AM (2010) A prospective study of the clinical impact of a multidisciplinary head and neck tumor board. Otolaryngol – Head Neck Surg 143:650–654CrossRefPubMedPubMedCentral Wheless SA, Mckinney KA, Zanation AM (2010) A prospective study of the clinical impact of a multidisciplinary head and neck tumor board. Otolaryngol – Head Neck Surg 143:650–654CrossRefPubMedPubMedCentral
Metadaten
Titel
Oncologic treatment landscape for head and neck squamous cell carcinoma
Treatment infrastructure in German-speaking countries
verfasst von
J. Kimmeyer
T. Kurzweg
T. K. Hoffmann
R. Knecht
J. A. Veit
N. Möckelmann
A. Münscher
Dr. S. Laban
Publikationsdatum
10.06.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
HNO / Ausgabe 7/2016
Print ISSN: 0017-6192
Elektronische ISSN: 1433-0458
DOI
https://doi.org/10.1007/s00106-016-0188-9

Weitere Artikel der Ausgabe 7/2016

HNO 7/2016 Zur Ausgabe

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.